As a new member of the PERT Consortium, inaugurated in 2015, NYP/Columbia is in the vanguard of treating pulmonary embolism with a rapid response, multidisciplinary team led by Philip Green, MD.
“We are able to manage any patient with thromboembolic disease by interventional, surgical, medical or combined approach, providing the highest level of patient care,” says Koji Takeda, MD, PhD, Adult ECMO Surgical Director and Pulmonary Thromboendarterectomy Program Director at Columbia.
A silent killer, PE is the third most common cause of death from cardiovascular disease, just after heart attack and stroke. With rapid diagnosis and treatment, survival rates can be significantly improved.
The PERT Consortium aims to guide and influence pulmonary embolism (PE) care and research in institutions across the U.S. and to become the driving force behind increased survival rates and future treatment.
Dr. Takeda is one of the few surgeons in the country who routinely addresses chronic thromboembolic pulmonary hypertension (CTEPH) with pulmonary thromboendarterectomy (PTE). This complex surgical procedure removes life-threatening chronic clots from a patient’s distal pulmonary arteries.
Read more about Columbia’s nationally recognized CTEPH/PTE program here.